­

About admin

This author has not yet filled in any details.
So far admin has created 70 blog entries.

OncBioMune Prepares Submission Seeking Marketing Approval for Anti-D Immunoglobulin in Mexico

BATON ROUGE, LA--(April 18, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged [...]

OncBioMune and Gem Pharmaceuticals Finalizing Partnership Terms to Develop New Cancer Drug for Mexico, Central and Latin America Markets

BATON ROUGE, LA--(March 30, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged [...]

OncBioMune Sales of Bekunis® and Cirkused® Exceed Forecast by 164 Percent in First Six Months on Market

BATON ROUGE, LA--(March 27, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico

BATON ROUGE, LA--(March 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

OncBioMune Announces Term Sheet with EOC Pharma for Development of Telatinib

BATON ROUGE, LA--(March 14, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network

BATON ROUGE, LA--(March 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

OncBioMune Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel [...]

Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials

BATON ROUGE, LA--(January 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

Departments of Urology and Oncology Approve Protocol for OncBioMune’s Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico

OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Submitting Clinical Trial of World’s First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute

BATON ROUGE, LA--(January 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]